Biblio

33557 resultats trouvés
P
Taieb J, Le Malicot K, Penault-Llorca FMadeleine, Bouche O, Shi Q, Thibodeau SN, Tabernero J, Mini E, Goldberg RM, Folprecht G et al..  2015.  Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX plus /- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. JOURNAL OF CLINICAL ONCOLOGY. 33
Vasseur A, Cabel L, Tredan O, Chevrier M, Dubot C, Lorgis V, Jacot W, Goncalves A, Debled M, Levy C et al..  2020.  Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). ANGIOGENESIS. 23:193-202.
Rambach L, Bertaut A, Vincent J, Lorgis V, Ladoire S, Ghiringhelli F.  2014.  Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. WORLD JOURNAL OF GASTROENTEROLOGY. 20:1565-1573.
Pernot S, Badoual C, Terme M, Castan F, Marcheteau E, Bouche O, Bennouna J, Francois E, Ghiringhelli F, de la Fouchardiere C et al..  2016.  Prognostic value of circulating tumor cells in advanced gastroesophageal adenocarcinomas in the randomized trial PRODIGE 17-MEGA (Unicancer GI-AGEO). JOURNAL OF CLINICAL ONCOLOGY. 34
Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CLong, Tibshirani R et al..  2019.  Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply. JOURNAL OF CLINICAL ONCOLOGY. 37:755+.
Pietrasz D, Wang-Renault S, Taieb J, Dahan L, Postel M, Durand-Labrunie J, Le Malicot K, Mulot C, Rinaldi Y, Phelip J-M et al..  2022.  Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. BRITISH JOURNAL OF CANCER. 126:440-448.
Cervoni J-P, Amoros A, Banares R, Montero JLuis, Soriano G, Weil D, Moreau R, Pavesi M, Thevenot T, Di Martino V et al..  2016.  Prognostic value of C-reactive protein in cirrhosis: external validation from the CANONIC cohort. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 28:1028-1034.
Cervoni JPaul, Alex A, Moreau R, Arroyo V, Jalan R, Saliba F, Durand F, Wendon J, Gustot T, Angeli P et al..  2014.  Prognostic value of C-reactive protein in patients with cirrhosis: external validation from the CANONIC cohort. HEPATOLOGY. 60:495A.
Cervoni JPaul, Alex A, Moreau R, Arroyo V, Jalan R, Saliba F, Durand F, Wendon J, Gustot T, Angeli P et al..  2014.  Prognostic value of C-reactive protein in patients with cirrhosis: external validation from the CANONIC cohort. HEPATOLOGY. 60:495A.
Di Martino V, Coutris C, Cervoni J-P, Dritsas S, Weil D, Richou C, Vanlemmens C, Thevenot T.  2015.  Prognostic value of C-reactive protein levels in patients with cirrhosis. LIVER TRANSPLANTATION. 21:753-760.
Di Martino V., Coutris C., Cervoni J.-P, Dritsas S., Weil D., Thevenot T..  2014.  PROGNOSTIC VALUE OF C-REACTIVE PROTEIN LEVELS IN PATIENTS WITH CIRRHOSIS. JOURNAL OF HEPATOLOGY. 60:S218.
Masson-Deshayes S, Schvartz C, Dalban C, Guendouzen S, Pochart J-M, Dalac A, Fieffe S, Bruna-Muraille C, Dabakuyo-Yonli TSandrine, Papathanassiou D.  2015.  Prognostic Value of F-18-FDG PET/CT Metabolic Parameters in Metastatic Differentiated Thyroid Cancers. CLINICAL NUCLEAR MEDICINE. 40:469-475.
Bailly C, Carlier T, Berriolo-Riedinger A, Casasnovas O, Gyan E, Meignan M, Moreau A, Burroni B, Djaileb L, Gressin R et al..  2020.  Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. HAEMATOLOGICA. 105:E33-E36.
Paquette B, Vernerey D, Anota A, Chauffert B, Dabakuyo TSandrine, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R et al..  2015.  Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. QUALITY OF LIFE RESEARCH. 24:90-91.
Paquette B, Vernerey D, Chauffert B, Dabakuyo S, Feuvret L, Taillandier L, Frappaz D, Taillia H, Schott R, Ducray F et al..  2016.  Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. CANCER MEDICINE. 5:1753-1764.
Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennelart H, Tredaniel J, Moro-Sibilot D, Herman D, Laize H, Masson P et al..  2016.  Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. EUROPEAN JOURNAL OF CANCER. 52:120-128.
Diouf M, Filleron T, Pointet A-L, Dupont-Gossard A-C, Malka D, Artru P, Gauthier M, Lecomte T, Aparicio T, Thirot-Bidault A et al..  2016.  Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. QUALITY OF LIFE RESEARCH. 25:1713-1723.
Canioni D, Brice P, Bologna S, Voillat L, Gabarre J, Casasnovas O, Devidas A, Coiffier B, Aoudjhane M, Audhuy B et al..  2018.  Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol. BLOOD. 132
Houvenaeghel G, Classe J-M, Garbay J-R, Giard S, Cohen M, Faure C, Helene C, Belichard C, Uzan S, Hudry D et al..  2014.  Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: A French sentinel node multicenter cohort study. BREAST. 23:561-566.
Taieb J, Emile J-F, Le Malicot K, Zaanan A, Tabernero J, Mini E, Rougier P, Van Laethem JLuc, Bridgewater JARes, Folprecht G et al..  2014.  Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. JOURNAL OF CLINICAL ONCOLOGY. 32
Blons H., Emile J.F, Le Malicot K., Julie C., Zaanan A., Tabernero J., Mini E., Folprecht G., Van Laethem J.L, Thaler J. et al..  2014.  Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. ANNALS OF ONCOLOGY. 25:2378-2385.
Dabi Y., Uzan J., Bendifallah S., Ouldamer L., Lavoue V., Canlorbe G., Raimond E., Coutant C., Graesslin O., Collinet P. et al..  2017.  Prognostic value of local relapse for patients with endometrial cancer. EJSO. 43:2143-2149.
Beurnier A, Graveleau J, Le Tourneau T, Masseau A, Degano B, Ricolleau B, Blanc F-X, Chambellan A.  2018.  Prognostic value of lung membrane conductance in sickle cell disease. EUROPEAN RESPIRATORY JOURNAL. 52
Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz J-F, Aparicio T, Folprecht G, Lepage C et al..  2018.  Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. CLINICAL CANCER RESEARCH. 24:4745-4753.
Gallois C., Taieb J., Le Corre D., Le Malicot K., Tabernero J., Mulot C., Seitz J-F., Aparicio T., Folprecht G., Lepage C. et al..  2017.  Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy. ANNALS OF ONCOLOGY. 28

Pages